OneSource Specialty Pharma, an Indian contract drug manufacturer, expects significant growth in its order book over the next three years, spurred by the global rise in demand for weight-loss drugs, the company’s CEO said on Monday.
As global pharmaceutical companies, including Indian generic drug manufacturers, rush to develop their own versions of blockbuster injectable obesity medications, OneSource is well-positioned to benefit. The injectable weight-loss drug Wegovy from Denmark’s Novo Nordisk, and similar treatments from Eli Lilly of the U.S., are expected to see a surge in competition as their patents near expiry. Novo’s semaglutide-based drug, for example, will lose its patent protection in 2026 in certain markets, including India.
OneSource, which specializes in developing complex biological drugs, injectables, and soft gelatin capsules for larger pharmaceutical firms, added 15 orders related to obesity and diabetes medications in fiscal year 2025. The company indicated that more orders are expected as the global obesity drug market is projected to reach \$150 billion by the early 2030s.
Neeraj Sharma, CEO of OneSource Specialty Pharma, emphasized that the company’s growth will be fueled by the upcoming commercial launches of GLP-1 drugs, a class of weight-loss and diabetes medications. These drugs are set to become available in key markets following the patent expiration in 2026. “Our growth over the next few years will be driven by the global launch of GLP-1s by our customers,” Sharma told Reuters in an interview.
According to the CEO, OneSource’s order book across all service segments is expected to grow at a 30% compound annual growth rate (CAGR) through fiscal year 2028, thanks to the growing demand for weight-loss drugs.
In line with this growth, OneSource is investing around \$100 million to expand its drug-device manufacturing facilities. The company, which was demerged from Strides Pharma Science and listed on the stock market in January, is also exploring opportunities to establish a global manufacturing presence, particularly in Europe and the U.S.
OneSource competes with larger contract manufacturers such as Piramal Pharma and Divi’s in the fields of research, development, and manufacturing. However, its strong positioning in the expanding market for obesity and diabetes medications is expected to set it apart in the coming years.
Related Topics:
US Fitness Company Plans 500 Million Crypto Treasury with FET Tokens
Interactive Fitness Market Size Share and Trends 2025 to 2034
Who Should Take Weight Loss Drugs Doctors Share Best Candidates
